Table 1 Baseline characteristics of studies and participants included
Trials, year | Drug | Size | Age (years) | BMI (kg/m2) | HbA1c,% | Follow-up duration | Outcomes of interest |
|---|---|---|---|---|---|---|---|
HARMONY 1, 2014 | Albiglutide | 301 | 55.0 | 34.1 | 8.1 | 52Â weeks | AF |
HARMONY 3, 2014 | Albiglutide | 1012 | 54.5 | 32.7 | 8.1 | 104Â weeks | SCD |
HARMONY 4, 2014 | Albiglutide | 745 | 55.5 | 33.1 | 8.3 | 52Â weeks | AF/AFL/VAs |
HARMONY 8, 2014 | Albiglutide | 495 | 63.3 | 30.4 | 8.2 | 52Â weeks | AF/AFL/VAs |
Rosenstock et al., 2014 | Albiglutide | 566 | 55.6 | NA | 8.5 | 26Â weeks | AF/VAs |
HARMONY 5, 2015 | Albiglutide | 663 | 55.2 | 32.2 | 8.2 | 52Â weeks | AF |
HARMONY 2, 2016 | Albiglutide | 301 | 52.9 | 33.9 | 8.2 | 52Â weeks | AF |
Harmony Outcomes, 2018 | Albiglutide | 9432 | 64.1 | 32.3 | 8.7 | 78Â weeks | AF/AFL/VAs/SCD |
Rosenstock et al., 2020 | Albiglutide | 813 | 58.1 | 32.1 | 7.7 | 26Â weeks | AF/AFL |
Ferdinand et al., 2014 | Dulaglutide | 755 | 56.5 | 33.0 | 7.9 | 26Â weeks | VAs |
AWARD-3, 2014 | Dulaglutide | 807 | 55.6 | 33.3 | 7.6 | 52Â weeks | AF |
AWARD-5, 2014 | Dulaglutide | 1098 | 54.0 | 31.3 | 8.1 | 52Â weeks | AF/SCD |
AWARD-2, 2015 | Dulaglutide | 807 | 56.6 | 31.6 | 8.1 | 78Â weeks | VAs |
AWARD-4, 2015 | Dulaglutide | 884 | 59.4 | 32.5 | 8.5 | 52Â weeks | AF/AFL/VAs |
AWARD-9, 2017 | Dulaglutide | 300 | 60.4 | 32.8 | 8.4 | 28Â weeks | AF |
AWARD-7, 2018 | Dulaglutide | 576 | 64.6 | 32.5 | 8.6 | 52Â weeks | AF/SCD |
AWARD-10, 2018 | Dulaglutide | 423 | 57.3 | 32.9 | 8.0 | 24Â weeks | AF |
Chen et al., 2018 | Dulaglutide | 735 | 52.8 | 25.9 | 8.0 | 26Â weeks | VAs |
REWIND, 2019 | Dulaglutide | 9892 | 66.2 | 32.3 | 7.3 | 282Â weeks | AF/AFL/VAs/SCD |
Heine et al., 2005 | Exenatide | 549 | 58.9 | 31.4 | 8.2 | 26Â weeks | AF |
Nauck et al., 2007 | Exenatide | 501 | 58.7 | 30.6 | 8.6 | 52Â weeks | AF/AFL |
NCT00701935, 2008 | Exenatide | 80 | 58.1 | NA | NA | 26Â weeks | AF |
EUREXA, 2012 | Exenatide | 1019 | 56.4 | 32.6 | 7.5 | 208Â weeks | AF/AFL |
DURATION-3, 2010 | Exenatide | 456 | 57.9 | 32.0 | 8.3 | 26Â weeks | SCD |
Inagaki et al., 2012 | Exenatide | 427 | 56.8 | 26.2 | 8.5 | 26Â weeks | AF |
Davies et al., 2013 | Exenatide | 216 | 58.5 | 33.7 | 8.4 | 26Â weeks | VAs |
LEAD-2, 2009 | Liraglutide | 1087 | 56.7 | 31.0 | 8.4 | 26Â weeks | AF/AFL/VAs/SCD |
LEAD-3 Mono, 2009 | Liraglutide | 746 | 53.0 | 33.1 | 8.3 | 104Â weeks | AF |
Pratley et al., 2010 | Liraglutide | 658 | 55.3 | 32.8 | 8.4 | 26Â weeks | SCD |
Charbonnel et al., 2012 | Liraglutide | 650 | 57.3 | 32.7 | 8.2 | 26Â weeks | AF |
MDI-Liraglutide, 2015 | Liraglutide | 124 | 63.7 | 33.7 | 9.0 | 24Â weeks | AF |
SCALE Obesity and Prediabetes, 2015 | Liraglutide | 3723 | 45.1 | 38.3 | 5.6 | 56Â weeks | AF/AFL/VAs/SCD |
Vanderheiden et al., 2016 | Liraglutide | 71 | 54.2 | 41.2 | NA | 26Â weeks | AF |
LEADER, 2016 | Liraglutide | 9340 | 64.3 | 32.5 | 8.7 | 198Â weeks | AF/AFL/VAs/SCD |
Zang et al., 2016 | Liraglutide | 367 | 51.5 | 27.2 | 8.1 | 26Â weeks | AF |
SCALE Insulin, 2020 | Liraglutide | 392 | 56.8 | 35.9 | 8.0 | 56Â weeks | AF/AFL |
GETGOAL-M, 2013 | Lixisenatide | 680 | 54.7 | 33.0 | 8.1 | 24Â weeks | AF/VAs |
GETGOAL-L, 2013 | Lixisenatide | 495 | 57.2 | 32.1 | 8.4 | 24Â weeks | AF/AFL |
GETGOAL-F1, 2014 | Lixisenatide | 482 | 56.1 | 32.5 | 8.0 | 24Â weeks | AF |
ELIXA, 2015 | Lixisenatide | 6063 | 60.3 | 30.2 | 7.7 | 107Â weeks | AF/AFL/VAs/SCD |
GetGoal-Duo-2, 2016 | Lixisenatide | 893 | 59.8 | 32.2 | 7.8 | 26Â weeks | AF |
PIONEER 2, 2019 | Oral semaglutide | 819 | 58.0 | 32.8 | 8.1 | 52Â weeks | AF/VAs |
PIONEER 3, 2019 | Oral semaglutide | 1861 | 58.0 | 32.5 | 8.3 | 78Â weeks | AF/AFL/SCD |
PIONEER 5, 2019 | Oral semaglutide | 324 | 70.0 | 32.4 | 8.0 | 26Â weeks | AF |
PIONEER 6, 2019 | Oral semaglutide | 3182 | 66.0 | 32.3 | 8.2 | 68Â weeks | AF/AFL/VAs/SCD |
PIONEER 8, 2019 | Oral semaglutide | 730 | 61.0 | 31.0 | 8.2 | 52Â weeks | AFL/VAs |
SUSTAIN 6, 2016 | Sc semaglutide | 3297 | 64.6 | 32.8 | 8.7 | 104Â weeks | AF/AFL/VAs/SCD |
SUSTAIN 2, 2017 | Sc semaglutide | 1225 | 55.1 | 32.5 | 8.1 | 56Â weeks | AF |
SUSTAIN 4, 2017 | Sc semaglutide | 1082 | 56.5 | 33.0 | 8.2 | 30Â weeks | AF |
Kaku et al., 2018 | Sc semaglutide | 600 | 58.5 | 26.4 | 8.1 | 56Â weeks | AF |
SUSTAIN China, 2021 | Sc semaglutide | 867 | 53.1 | 28.0 | 8.1 | 30Â weeks | AF/VAs |
STEP 1, 2021 | Sc semaglutide | 1961 | 46.0 | 37.8 | 5.7 | 68Â weeks | AF |
STEP 2, 2021 | Sc semaglutide | 1207 | 55.0 | 35.7 | 8.1 | 68Â weeks | AF |
STEP 4, 2021 | Sc semaglutide | 803 | 46.0 | 34.1 | 5.4 | 68Â weeks | AF |
STEP 6, 2022 | Sc semaglutide | 400 | 51.0 | 31.9 | 6. | 68Â weeks | AF |
SUSTAIN 11, 2022 | Sc semaglutide | 1738 | 61.2 | 31.5 | 8.6 | 52Â weeks | AF/AFL/SCD |